Pharmacology Quiz: Metabolism And Cyp450
20 questions · exam conditions
0:00
Metabolism And Cyp450Question 1 of 20

A patient with breast cancer is found to be a CYP2D6 poor metabolizer due to a genetic polymorphism. She is prescribed tamoxifen as part of her treatment plan. What is the most likely clinical consequence of this patient's phenotype on her tamoxifen therapy?

An increased risk of tamoxifen-related adverse effects, such as hot flashes and nausea.
A decreased risk of developing resistance to tamoxifen over the course of therapy.
A reduced therapeutic efficacy due to insufficient formation of its active metabolite.
A significantly prolonged half-life of tamoxifen, requiring less frequent dosing.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Metabolism And Cyp450

Practice Metabolism And Cyp450 in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Metabolism And Cyp450, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A patient with breast cancer is found to be a CYP2D6 poor metabolizer due to a genetic polymorphism. She is prescribed tamoxifen as part of her treatment plan. What is the most likely clinical consequence of this patient's phenotype on her tamoxifen therapy?

  1. An increased risk of tamoxifen-related adverse effects, such as hot flashes and nausea.
  2. A decreased risk of developing resistance to tamoxifen over the course of therapy.
  3. A reduced therapeutic efficacy due to insufficient formation of its active metabolite. (correct answer)
  4. A significantly prolonged half-life of tamoxifen, requiring less frequent dosing.
Explanation: Tamoxifen is a prodrug that requires bioactivation by CYP2D6 to its primary active metabolite, endoxifen. In a patient who is a CYP2D6 poor metabolizer, this conversion is significantly reduced. This leads to lower plasma concentrations of endoxifen, resulting in decreased anti-estrogenic effect and reduced therapeutic efficacy against estrogen receptor-positive breast cancer.

Question 2

A patient with Gilbert's syndrome has a mild genetic deficiency in the UGT1A1 enzyme. This condition primarily affects the metabolism of endogenous bilirubin. Which of the following drug metabolism pathways would most likely also be impaired in this patient?

  1. Oxidation of a beta-blocker by CYP2D6.
  2. Acetylation of isoniazid by N-acetyltransferase 2 (NAT2).
  3. Glucuronidation of irinotecan's active metabolite, SN-38. (correct answer)
  4. Hydrolysis of aspirin to salicylic acid by esterases.
Explanation: Gilbert's syndrome is caused by reduced activity of UDP-glucuronosyltransferase 1A1 (UGT1A1). This same enzyme is responsible for the Phase II glucuronidation of SN-38, the active metabolite of the chemotherapy drug irinotecan. Patients with Gilbert's syndrome have a decreased ability to clear SN-38, leading to an increased risk of severe toxicity, such as neutropenia and diarrhea. The other options involve different, unrelated metabolic pathways.

Question 3

The nomenclature 'CYP3A4' provides specific information about the enzyme. What does the '3' in CYP3A4 correctly signify?

  1. The subfamily, which groups enzymes with >55% amino acid identity.
  2. The specific gene product within the subfamily.
  3. The chromosomal location of the gene that codes for the enzyme.
  4. The family, which groups enzymes with >40% amino acid identity. (correct answer)
Explanation: In the cytochrome P450 nomenclature, the number immediately following 'CYP' indicates the gene family. Enzymes within the same family share at least 40% amino acid sequence homology. The letter ('A') designates the subfamily (>55% homology), and the final number ('4') indicates the individual gene.

Question 4

A patient with a genetic deficiency in NADPH-cytochrome P450 oxidoreductase (POR) is administered a drug that is exclusively metabolized by CYP3A4-mediated oxidation. What is the most probable pharmacokinetic consequence for this drug in this patient?

  1. A significant decrease in the rate of metabolic clearance. (correct answer)
  2. A compensatory increase in Phase II conjugation of the parent drug.
  3. An increase in the oral bioavailability due to reduced first-pass metabolism.
  4. A rapid shift to elimination via non-CYP pathways like alcohol dehydrogenase.
Explanation: NADPH-cytochrome P450 oxidoreductase (POR) is an essential enzyme that transfers electrons from NADPH to all microsomal cytochrome P450 enzymes, including CYP3A4. This electron transfer is a required step for the catalytic activity of P450s. A deficiency in POR would impair the function of CYP3A4, leading to a significant decrease in the metabolic clearance of any drug that is a substrate for it.

Question 5

Cats are known to be highly susceptible to acetaminophen toxicity compared to dogs or humans. This species-specific sensitivity is primarily due to a relative deficiency in which specific metabolic pathway, leading to increased formation of the toxic metabolite NAPQI?

  1. Sulfate conjugation (sulfation).
  2. Glucuronide conjugation (glucuronidation). (correct answer)
  3. CYP2E1-mediated oxidation.
  4. Glutathione conjugation.
Explanation: The primary, non-toxic route of acetaminophen metabolism in most species is Phase II glucuronidation. Cats have a genetic deficiency in the specific UDP-glucuronosyltransferase isoforms required for this process. The inability to efficiently conjugate acetaminophen with glucuronic acid shunts a larger fraction of the dose down the alternative CYP-mediated oxidation pathway, leading to excessive production of the hepatotoxic metabolite NAPQI, even at doses that would be safe for other species.

Question 6

A patient taking selegiline, a selective MAO-B inhibitor, for Parkinson's disease is instructed to avoid foods high in tyramine. While selegiline at low doses is selective for MAO-B in the brain, why does this dietary restriction remain important?

  1. High tyramine concentrations can overcome the selectivity and inhibit MAO-B in the gut.
  2. At higher doses or with certain formulations, selegiline loses its selectivity and also inhibits MAO-A in the gut wall and liver. (correct answer)
  3. Tyramine is also a substrate for CYP2D6, and selegiline is a potent inhibitor of this enzyme.
  4. Selegiline undergoes Phase II metabolism, which is saturated by tyramine, leading to selegiline toxicity.
Explanation: MAO-A is the primary enzyme responsible for metabolizing dietary tyramine in the gastrointestinal tract and liver. While selegiline is selective for MAO-B at low doses used for Parkinson's, this selectivity is lost at higher doses. Ingesting tyramine-rich foods can lead to a hypertensive crisis because the un-metabolized tyramine acts as an indirect sympathomimetic, releasing large amounts of norepinephrine.

Question 7

A drug's metabolic profile reveals that it undergoes N-acetylation. The patient population shows a bimodal distribution for the rate of this reaction, with distinct 'slow acetylator' and 'fast acetylator' phenotypes. This polymorphism is most likely due to genetic variation in which of the following enzymes?

  1. CYP2C19
  2. UDP-glucuronosyltransferase (UGT)
  3. Thiopurine S-methyltransferase (TPMT)
  4. N-acetyltransferase 2 (NAT2) (correct answer)
Explanation: The bimodal distribution of acetylation speed is the classic presentation of genetic polymorphism in the N-acetyltransferase 2 (NAT2) enzyme. This Phase II enzyme is responsible for the metabolism of various drugs, including isoniazid, hydralazine, and procainamide. Individuals can be classified as slow, intermediate, or rapid acetylators based on their NAT2 genotype, which can have significant clinical implications for drug efficacy and toxicity.

Question 8

A patient on a stable dose of theophylline for asthma develops a urinary tract infection and is prescribed ciprofloxacin. Theophylline is primarily metabolized by CYP1A2. Ciprofloxacin is a known inhibitor of CYP1A2. Which pharmacokinetic parameter of theophylline is most likely to be decreased, and what is the potential clinical consequence?

  1. Volume of distribution; leading to subtherapeutic plasma concentrations.
  2. Oral bioavailability; resulting in a diminished therapeutic effect.
  3. Total body clearance; increasing the risk of toxicity like seizures and arrhythmias. (correct answer)
  4. Half-life; requiring more frequent dosing to maintain therapeutic levels.
Explanation: Ciprofloxacin inhibits CYP1A2, the enzyme responsible for theophylline metabolism. This inhibition reduces the rate at which theophylline is cleared from the body, thus decreasing its total body clearance. A decrease in clearance leads to an increase in the drug's half-life and steady-state concentration, significantly raising the risk of theophylline toxicity, which can manifest as seizures and cardiac arrhythmias.

Question 9

A patient stabilized on warfarin (a narrow therapeutic index substrate of CYP2C9) for atrial fibrillation is diagnosed with tuberculosis. A multi-drug regimen including rifampin is initiated. Two weeks later, the patient's International Normalized Ratio (INR) is found to be 1.1 (therapeutic range is 2.0-3.0). Which of the following best explains this finding?

  1. Rifampin inhibited the metabolism of warfarin, leading to a subtherapeutic INR.
  2. Rifampin induced the metabolism of warfarin, leading to a subtherapeutic INR. (correct answer)
  3. Warfarin induced the metabolism of rifampin, leading to decreased rifampin efficacy.
  4. Rifampin displaced warfarin from plasma proteins, increasing its clearance and leading to a low INR.
Explanation: Rifampin is a potent inducer of several cytochrome P450 enzymes, including CYP2C9. Warfarin is metabolized by CYP2C9. By inducing this enzyme, rifampin increases the metabolic clearance of warfarin, leading to lower plasma concentrations and a reduced anticoagulant effect. This is reflected in a decreased (subtherapeutic) INR.

Question 10

A full-term neonate requires a medication that is primarily cleared from the body by Phase II glucuronidation. How would the half-life of this drug in the neonate compare to its half-life in a healthy adult, and what is the physiological basis for this difference?

  1. Shorter half-life, due to the neonate's higher liver-to-body-mass ratio.
  2. Longer half-life, due to the immaturity of UDP-glucuronosyltransferase (UGT) enzyme systems. (correct answer)
  3. Similar half-life, as underdeveloped renal function is balanced by a lower volume of distribution.
  4. Longer half-life, due to decreased expression of Phase I enzymes like CYP3A4.
Explanation: Neonates, particularly premature infants, have underdeveloped Phase II metabolic pathways. The activity of UDP-glucuronosyltransferase (UGT) enzymes, which are responsible for glucuronidation, is significantly lower than in adults. This reduced metabolic capacity leads to decreased clearance and a prolonged elimination half-life for drugs that rely on this pathway, increasing the risk of accumulation and toxicity (e.g., chloramphenicol and gray baby syndrome).

Question 11

A drug is metabolized via two parallel pathways. Pathway A is a high-capacity, low-affinity Phase II conjugation reaction. Pathway B is a low-capacity, high-affinity Phase I oxidation reaction via CYP3A4 that produces a reactive, toxic metabolite. In an overdose situation, why does the risk of toxicity from this drug dramatically increase?

  1. The Phase II conjugation pathway becomes saturated, shunting the drug toward the toxic Phase I pathway. (correct answer)
  2. The high concentration of drug induces the CYP3A4 enzyme, accelerating production of the toxic metabolite.
  3. The Phase I pathway becomes saturated, causing the parent drug itself to accumulate to toxic levels.
  4. The cofactors required for the Phase II pathway are depleted, causing inhibition of the primary clearance route.
Explanation: This scenario mirrors acetaminophen toxicity. At therapeutic doses, the drug is primarily cleared by high-capacity Phase II pathways (like glucuronidation and sulfation). In an overdose, these pathways become saturated. The excess drug is then shunted to the Phase I (CYP) pathway, leading to a massive increase in the production of the toxic metabolite. Cofactor depletion (specifically glutathione for NAPQI) also occurs, but the initial shunt is due to saturation of the primary pathway.

Question 12

A patient is started on atorvastatin. Atorvastatin itself is active, but it is also metabolized by CYP3A4 to form two active metabolites. If this patient simultaneously starts taking clarithromycin, a potent CYP3A4 inhibitor, what is the expected net effect on the therapeutic and toxic potential of the statin therapy?

  1. Decreased therapeutic effect because the formation of active metabolites is blocked.
  2. Increased therapeutic effect and increased risk of myopathy due to accumulation of the parent drug. (correct answer)
  3. No significant change in effect, as the decrease in active metabolites is offset by the increase in the parent drug.
  4. Increased therapeutic effect but a decreased risk of toxicity, as the toxic metabolites are not formed.
Explanation: Clarithromycin inhibits CYP3A4, which is responsible for clearing the active parent drug, atorvastatin. While the formation of atorvastatin's active metabolites will decrease, the accumulation of the parent drug, which is itself potent, will be the dominant effect. This leads to a substantial increase in overall statin exposure, enhancing both the therapeutic (lipid-lowering) effect and, more critically, the risk of concentration-dependent toxicity such as myopathy and rhabdomyolysis.

Question 13

The oral bioavailability of a new drug is extremely low (~5%) due to a very high hepatic first-pass effect. The drug is classified as a high-extraction-ratio drug. How would co-administration of a potent CYP3A4 inducer, the primary metabolizing enzyme, affect the oral bioavailability and systemic clearance of this drug?

  1. Bioavailability would decrease significantly, and clearance would increase significantly.
  2. Bioavailability would be unchanged, but clearance would increase significantly.
  3. Bioavailability would decrease slightly, and clearance would be largely unchanged. (correct answer)
  4. Bioavailability would decrease significantly, and clearance would be largely unchanged.
Explanation: For high-extraction-ratio drugs, systemic clearance is limited by hepatic blood flow, not by enzymatic activity. Therefore, inducing the metabolizing enzymes (e.g., with an inducer) has little to no effect on systemic clearance. However, induction of enzymes in the gut wall and liver will increase the amount of drug metabolized before it reaches systemic circulation (first-pass metabolism), leading to a further, albeit slight, decrease in its already low oral bioavailability.

Question 14

A small increase in the daily dose of phenytoin leads to a disproportionately large increase in the steady-state plasma concentration and the onset of nystagmus and ataxia. This nonlinear pharmacokinetic behavior is best explained by:

  1. A dose-dependent decrease in plasma protein binding.
  2. Saturation of the hepatic enzymes responsible for its metabolism. (correct answer)
  3. Inhibition of P-glycoprotein efflux transporters in the blood-brain barrier.
  4. Auto-inhibition of its own metabolic pathways at higher concentrations.
Explanation: Phenytoin exhibits Michaelis-Menten (saturable) kinetics. At low doses, metabolism is first-order, where the rate of elimination is proportional to the drug concentration. However, at therapeutic concentrations, the primary metabolizing enzymes (CYP2C9 and CYP2C19) become saturated. At this point, the metabolism shifts to zero-order kinetics, where a constant amount of drug is eliminated per unit time. A small increase in dose can overwhelm the saturated system, leading to a large, nonlinear increase in plasma levels and toxicity.

Question 15

A patient with breast cancer is found to be a CYP2D6 poor metabolizer due to a genetic polymorphism. She is prescribed tamoxifen as part of her treatment plan. What is the most likely clinical consequence of this patient's phenotype on her tamoxifen therapy?

  1. An increased risk of tamoxifen-related adverse effects, such as hot flashes and nausea.
  2. A decreased risk of developing resistance to tamoxifen over the course of therapy.
  3. A reduced therapeutic efficacy due to insufficient formation of its active metabolite. (correct answer)
  4. A significantly prolonged half-life of tamoxifen, requiring less frequent dosing.
Explanation: Tamoxifen is a prodrug that requires bioactivation by CYP2D6 to its primary active metabolite, endoxifen. In a patient who is a CYP2D6 poor metabolizer, this conversion is significantly reduced. This leads to lower plasma concentrations of endoxifen, resulting in decreased anti-estrogenic effect and reduced therapeutic efficacy against estrogen receptor-positive breast cancer.

Question 16

A patient receiving chronic therapy with carbamazepine for seizures requires the addition of a new medication. After four weeks on a stable dose of carbamazepine, its trough plasma concentration is measured and found to be 40% lower than the concentration measured after three days of therapy, despite consistent adherence. This observation is best explained by:

  1. Saturation of plasma protein binding sites, leading to increased free drug clearance.
  2. Development of pharmacodynamic tolerance at the neuronal level.
  3. Auto-induction of CYP3A4 enzymes responsible for its own metabolism. (correct answer)
  4. Progressive increase in renal clearance due to improved kidney function.
Explanation: Carbamazepine is a well-known auto-inducer of its own metabolism. It induces the expression of CYP3A4, the primary enzyme that metabolizes it. This process takes several weeks to reach its maximum effect. As a result, the rate of carbamazepine clearance increases over time, leading to a decrease in its steady-state plasma concentration on a stable dose.

Question 17

The oral bioavailability of a new drug is extremely low (~5%) due to a very high hepatic first-pass effect. The drug is classified as a high-extraction-ratio drug. How would co-administration of a potent CYP3A4 inducer, the primary metabolizing enzyme, affect the oral bioavailability and systemic clearance of this drug?

  1. Bioavailability would decrease significantly, and clearance would increase significantly.
  2. Bioavailability would be unchanged, but clearance would increase significantly.
  3. Bioavailability would decrease slightly, and clearance would be largely unchanged. (correct answer)
  4. Bioavailability would decrease significantly, and clearance would be largely unchanged.
Explanation: For high-extraction-ratio drugs, systemic clearance is limited by hepatic blood flow, not by enzymatic activity. Therefore, inducing the metabolizing enzymes (e.g., with an inducer) has little to no effect on systemic clearance. However, induction of enzymes in the gut wall and liver will increase the amount of drug metabolized before it reaches systemic circulation (first-pass metabolism), leading to a further, albeit slight, decrease in its already low oral bioavailability.

Question 18

A patient on a stable dose of theophylline for asthma develops a urinary tract infection and is prescribed ciprofloxacin. Theophylline is primarily metabolized by CYP1A2. Ciprofloxacin is a known inhibitor of CYP1A2. Which pharmacokinetic parameter of theophylline is most likely to be decreased, and what is the potential clinical consequence?

  1. Volume of distribution; leading to subtherapeutic plasma concentrations.
  2. Oral bioavailability; resulting in a diminished therapeutic effect.
  3. Total body clearance; increasing the risk of toxicity like seizures and arrhythmias. (correct answer)
  4. Half-life; requiring more frequent dosing to maintain therapeutic levels.
Explanation: Ciprofloxacin inhibits CYP1A2, the enzyme responsible for theophylline metabolism. This inhibition reduces the rate at which theophylline is cleared from the body, thus decreasing its total body clearance. A decrease in clearance leads to an increase in the drug's half-life and steady-state concentration, significantly raising the risk of theophylline toxicity, which can manifest as seizures and cardiac arrhythmias.

Question 19

A patient taking selegiline, a selective MAO-B inhibitor, for Parkinson's disease is instructed to avoid foods high in tyramine. While selegiline at low doses is selective for MAO-B in the brain, why does this dietary restriction remain important?

  1. High tyramine concentrations can overcome the selectivity and inhibit MAO-B in the gut.
  2. At higher doses or with certain formulations, selegiline loses its selectivity and also inhibits MAO-A in the gut wall and liver. (correct answer)
  3. Tyramine is also a substrate for CYP2D6, and selegiline is a potent inhibitor of this enzyme.
  4. Selegiline undergoes Phase II metabolism, which is saturated by tyramine, leading to selegiline toxicity.
Explanation: MAO-A is the primary enzyme responsible for metabolizing dietary tyramine in the gastrointestinal tract and liver. While selegiline is selective for MAO-B at low doses used for Parkinson's, this selectivity is lost at higher doses. Ingesting tyramine-rich foods can lead to a hypertensive crisis because the un-metabolized tyramine acts as an indirect sympathomimetic, releasing large amounts of norepinephrine.

Question 20

A patient taking felodipine, a CYP3A4 substrate, for hypertension consumes a large amount of grapefruit juice daily. This results in a significant increase in the drug's plasma concentration and signs of toxicity (e.g., hypotension). The primary mechanism for this interaction is:

  1. Mechanism-based inhibition of CYP3A4 primarily in the intestinal enterocytes. (correct answer)
  2. Increased absorption of felodipine due to a change in gastric pH caused by the juice.
  3. Competitive inhibition of systemic hepatic CYP3A4 by components in grapefruit juice.
  4. Induction of renal transporters, leading to decreased elimination of felodipine.
Explanation: When you encounter drug interaction questions involving grapefruit juice, think about CYP3A4 enzyme inhibition and where it occurs in the body. The grapefruit-drug interaction is a classic example of how food can dramatically alter drug metabolism. Grapefruit juice contains furanocoumarins (like bergamottin) that cause mechanism-based inhibition of CYP3A4. This type of inhibition is irreversible - the compounds bind covalently to the enzyme and permanently inactivate it. The key insight is that this interaction occurs primarily in intestinal enterocytes, not the liver. When felodipine is taken orally, it normally undergoes extensive first-pass metabolism in the gut wall via CYP3A4. Grapefruit juice knocks out these intestinal enzymes, allowing much more unchanged drug to reach systemic circulation, explaining the dramatic increase in plasma levels and toxicity. Option B is incorrect because grapefruit juice doesn't significantly alter gastric pH or enhance drug absorption directly. Option C mislocates the primary site of interaction - while grapefruit components might reach the liver, the intestinal effect is much more clinically significant, and the inhibition isn't competitive but mechanism-based. Option D incorrectly suggests renal transporter induction, but grapefruit interactions primarily affect metabolism, not elimination, and felodipine is metabolized rather than renally excreted unchanged. Remember this pattern: grapefruit juice + CYP3A4 substrate = increased drug levels due to intestinal enzyme inhibition. This interaction can persist for days since new enzymes must be synthesized to replace the inactivated ones.